GI Dynamics, Inc. - ASX Announcement

GI Dynamics, Inc. Announces Commercial Availability of the EndoBarrier® for the Treatment of Type 2 Diabetes and/or Obesity in the Netherlands

Lexington, Mass., United States and Sydney, Australia - January 4, 2012 - GI Dynamics, Inc. (ASX: GID) today announced the transition of the EndoBarrier® Gastrointestinal Liner (the EndoBarrier), a novel, non-surgical device for the treatment of type 2 diabetes and/or obesity, from clinical research to commercial use in the Netherlands. To date, nearly 100 patients have been treated with the EndoBarrier in clinical trials conducted in the Netherlands.

"We have studied the EndoBarrier for several years and are very happy with the improvements in blood sugar and weight loss our patients have achieved," said Ignace Janssen, M.D., clinical study investigator and bariatric surgeon, Vitalys Obesitas Centrum, Rijnstate Hospital,
Arnhem, Netherlands. "Our clinical experience has given us a keen understanding of the type
2 diabetes patients and/or obese patients who would be good candidates for EndoBarrier therapy. Additionally, it has helped us develop the optimal treatment program that will help ensure successful outcomes for our patients."
Martin Kirch, director of Vitalys Clinics added, "The EndoBarrier is filling a gap in our treatment paradigm. In particular, we believe it can help obese diabetic patients in the lower BMI range. The EndoBarrier provides an approach to better manage type 2 diabetes and related comorbidities for these patients."
The EndoBarrier has received European CE mark approval and is commercially available
in Chile, Germany, the United Kingdom, the Netherlands and Austria. The EndoBarrier has also received TGA approval and will soon be available in Australia.
"We are delighted that the EndoBarrier is now being offered commercially through this Center of Excellence in the Netherlands," said Stuart A. Randle, president and chief executive officer, GI Dynamics. "In particular, the success this center has had implanting the EndoBarrier under conscious sedation is very exciting and could potentially translate into reduced costs and even more rapid recovery. These are important milestones for the company as we expand from clinical to commercial use in key European markets."
The EndoBarrier is a thin, flexible, tube-shaped liner that forms a physical barrier between food and a portion of the wall of the intestine. It has been clinically proven to lower HbA1c levels,
www.gidynamics.com

US OFFICE & HEADQUARTERS: 1 Maguire Road, Lexington MA 02421 T +1 (781) 357